{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:14:54Z","timestamp":1791065694910,"version":"4.1.0"},"reference-count":61,"publisher":"JLE","issue":"7","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.nephro.2008.10.002","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T10:47:57Z","timestamp":1227350877000},"page":"602-615","source":"Crossref","is-referenced-by-count":67,"title":["Effets vasculaires et r\u00e9naux des m\u00e9dicaments anti-angiog\u00e9niques\u00a0: recommandations fran\u00e7aises pour la pratique (SN, SFHTA, APNET, FFCD)"],"prefix":"10.1684","volume":"4","author":[{"given":"Jean-Michel","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bobrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"des Guetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Nochy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dil","family":"Sahali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2008.10.002_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1359-6349(08)70290-8","article-title":"Management of toxicity in patients receiving therapy with bevacizumab","author":"Miles","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nephro.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nephro.2008.10.002_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"4","author":"Ferrara","year":"2004","journal-title":"Endocrine Rev"},{"key":"10.1016\/j.nephro.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alpha in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/jco.2007.25.18_suppl.lba1","article-title":"Sorafenib improves survival in advanced hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"741s","DOI":"10.1158\/1078-0432.CCR-06-2110","article-title":"Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma","volume":"13","author":"Rini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2008.10.002_bib11","first-page":"3","article-title":"Cancer incidence and mortality in France over the period 1978\u20132000","volume":"51","author":"Remontet","year":"2003","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.nephro.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.nephro.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","article-title":"The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA","volume":"5","author":"Houck","year":"1991","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.nephro.2008.10.002_bib16","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","article-title":"The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing","volume":"266","author":"Tischer","year":"1991","journal-title":"J Biol Chem"},{"issue":"77","key":"10.1016\/j.nephro.2008.10.002_bib17","first-page":"88","article-title":"The carboxyl-terminal domain (111\u2013165) of vascular endothelial growth factor is critical for its mitogenic potency","volume":"271","author":"Keyt","year":"1996","journal-title":"J Biol Chem."},{"key":"10.1016\/j.nephro.2008.10.002_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ctrv.2007.09.003","article-title":"New developments in multitargeted therapy for patients with solid tumours","volume":"34","author":"Le Tourneau","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nephro.2008.10.002_bib19","first-page":"4593","article-title":"Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.nephro.2008.10.002_bib20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0969-2126(98)00116-6","article-title":"VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface","volume":"6","author":"Muller","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.nephro.2008.10.002_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nephro.2008.10.002_bib22","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 18S","key":"10.1016\/j.nephro.2008.10.002_bib24","doi-asserted-by":"crossref","first-page":"4034a","DOI":"10.1200\/jco.2007.25.18_suppl.4034","article-title":"Comparable safety and response rate with bevacizumab in combination with capecitabine\/oxaliplatin (CapOx\/Bev) versus capecitabine\/irinotecan (CapIri\/Bev) in advanced CRC (mCRC)","volume":"25","author":"Schmiegel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2008.10.002_bib26","first-page":"243s","article-title":"Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers","volume":"25","author":"George","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib27","unstructured":"http:\/\/ctep.cancer.gov\/reporting\/ctc.html (site consult\u00e9 le 8 septembre 2008)."},{"key":"10.1016\/j.nephro.2008.10.002_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib29","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2008.10.002_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2008.10.002_bib34","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib35","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2008.10.002_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ndt\/gfm199","article-title":"Interstitial nephritis in a patient taking sorafenib","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2008.10.002_bib37","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGFantibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangi\u00e9","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib39","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2008.10.002_bib40","doi-asserted-by":"crossref","unstructured":"Ayllon J, Janus N, Launay-Vacher V, et al. Anti-VEGF therapies, cancer and renal function. J Clin Oncol 26: 2008 suppl; abstr 16001.","DOI":"10.1200\/jco.2008.26.15_suppl.16001"},{"key":"10.1016\/j.nephro.2008.10.002_bib41","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2008.10.002_bib42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2008.10.002_bib43","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib44","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2008.10.002_bib45","unstructured":"http:\/\/www.has-sante.fr\/portail\/display.jsp?id=c_272459 (site consult\u00e9 le 8 septembre 2008)."},{"key":"10.1016\/j.nephro.2008.10.002_bib46","unstructured":"http:\/\/afssaps.sante.fr\/htm\/5\/liste_tensio_1.htm (site consult\u00e9 le 8 septembre 2008)."},{"key":"10.1016\/j.nephro.2008.10.002_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2008.10.002_bib49","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","article-title":"ESH-ESC practice guidelines for the management of arterial hypertension","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.nephro.2008.10.002_bib50","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMc070327","article-title":"Sunitinib and hypothyroidism","volume":"356","author":"Wolter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of Sunitinib activity","volume":"18","author":"Rixe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib52","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2007.11.5113","article-title":"Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?","volume":"25","author":"van Heeckeren","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2008.10.002_bib54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1345\/aph.1H244","article-title":"Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension","volume":"40","author":"Dincer","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nephro.2008.10.002_bib55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.nephro.2008.10.002_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1H635","article-title":"Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma","volume":"41","author":"Barakat","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nephro.2008.10.002_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib58","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2007.01.002","article-title":"Angiogenesis inhibitors in the treatment of lung cancer","volume":"62","author":"Sun","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nephro.2008.10.002_bib60","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2008.10.002_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725508002514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725508002514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2008.10.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:26:07Z","timestamp":1741184767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725508002514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1769725508002514"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2008.10.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}